Sanofi-Genzyme has remained committed to the goal identified during their founding in 1981 – to seek out unmet medical needs and find ways to meet these needs. Over the years it has developed a number of breakthrough medical treatments that are improving the lives of patients all over the world, and continues to advance new therapies. Sanofi-Genzyme was the first company to develop treatments for ultra-orphan diseases with less than 10,000 patients worldwide, and the business model they pioneered has spurred others to address rare genetic diseases.
Sanofi-Genzyme Oncology is a leader in the effort to develop and apply the most advanced technologies to hematologic oncology and other areas of cancer. Current products are focused on leukemia, lymphoma and stem cell transplant.

More about:


Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1 billion doses of vaccine each year, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur produces a portfolio of high quality vaccines that matches its areas of expertise and meets public-health demand. The company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR 1 million in research and development.

Sanofi-Pasteur products:

  • Verorab
  • Vaxigrip
  • Shan5
  • Imovax Polio
  • Stamaril
  • Pentaxim
  • Tetraxim
  • Hexaxim
  • Adacel
  • Adacel Polio
  • Act-Hib
  • Shanchol